Search

Your search keyword '"Salwender, Hans"' showing total 6 results
Start Over Author "Salwender, Hans" Journal blood cancer journal
6 results on '"Salwender, Hans"'

1. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Author

Moreau, Philippe, Chari, Ajai, Oriol, Albert, Martinez-Lopez, Joaquin, Haenel, Mathias, Touzeau, Cyrille, Ailawadhi, Sikander, Besemer, Britta, de la Rubia Comos, Javier, Encinas, Cristina, Mateos, Maria-Victoria, Salwender, Hans, Rodriguez-Otero, Paula, Hulin, Cyrille, Karlin, Lionel, Sureda Balari, Anna, Bargay, Joan, Benboubker, Lotfi, Rosiñol, Laura, Tarantolo, Stefano, Terebelo, Howard, Yang, Shiyi, Wang, Jianping, Nnane, Ivo, Qi, Ming, Kosh, Michele, Delioukina, Maria, and Goldschmidt, Hartmut

Published
2023
Full Text
View/download PDF

3. Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

Author

Merz, Maximilian, Hielscher, Thomas, Mai, Elias Karl, Seckinger, Anja, Hose, Dirk, Jauch, Anna, Sauer, Sandra, Luntz, Steffen, Bertsch, Uta, Raab, Marc S., Neben, Kai, Salwender, Hans, Blau, Igor W., Lindemann, Hans-Walter, Dürig, Jan, Scheid, Christof, Haenel, Mathias, Weisel, Katja, Weber, Tim, Delorme, Stefan, Goldschmidt, Hartmut, and Hillengass, Jens

Published
2019
Full Text
View/download PDF

5. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Author

Kriegsmann, Katharina, primary, Baertsch, Marc-Andrea, additional, Awwad, Mohamed H. S., additional, Merz, Maximilian, additional, Hose, Dirk, additional, Seckinger, Anja, additional, Jauch, Anna, additional, Becker, Natalia, additional, Benner, Axel, additional, Raab, Marc S., additional, Hillengass, Jens, additional, Bertsch, Uta, additional, Dürig, Jan, additional, Salwender, Hans Jürgen, additional, Hänel, Mathias, additional, Fenk, Roland, additional, Munder, Markus, additional, Weisel, Katja, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, and Hundemer, Michael, additional

Published
2019
Full Text
View/download PDF

6. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Author

Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, and Lokhorst, Henk

Subjects
BORTEZOMIB, ANTINEOPLASTIC agents, DRUG efficacy, MULTIPLE myeloma treatment, STEM cell transplantation, CANCER chemotherapy, CLINICAL trials
Abstract

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results